BUENOS AIRES, Argentina, June 24, 2015 /PRNewswire/ -- Ariel Fernandez Consultancy serves the biotechnology industry by harnessing fundamental discoveries to broaden its technological base. In line with this goal, Richard L. Moss in collaboration with Ariel Fernandez invented a new drug for the molecularly targeted treatment of heart failure. By binding competitively to the myosin regulator MyBP-C, the novel drug disrupts the myosin-MyBP-C association, releasing the "molecular brakes" that cause heart failure.
The invention was awarded US patent 9,051,387 and constitutes the first treatment based on rational design. The molecular target was discovered by Richard Moss, while the drug was created by Ariel Fernandez based on molecular engineering concepts like the "dehydron" described in Fernandez's book "Biomolecular Interfaces" (Springer, 2015).
Ariel Fernandez Consultancy addresses scientific needs of the pharmaceutical industry, seeking to provide the kind of thought leadership that translates into a competitive advantage. The consultancy harnesses novel scientific innovation to design prototypes with optimized safety, controlled specificity and therapeutic potency.
The therapeutic disruption of a protein-protein association is considered one of the most challenging problems in drug discovery. This invention solves the problem, providing a molecular targeted therapy for heart failure.
CEO Ariel Fernandez Consultancy/Former Professor at Rice University, USA
Ariel Fernandez, Ph. D.
This release was issued through WebWire®. For more information, visit http://www.webwire.com.
SOURCE Ariel Fernandez Consultancy